Identification of novel estrogen receptor (ER) agonists that have additional and complementary anti-cancer activities via ER-independent mechanism
摘要:
In this study, a series of bis(4-hydroxy) benzophenone oxime ether derivatives such as 12c, 12e and 12h were identified as novel estrogen receptor (ER) agonists that have additional and complementary anti-proliferative activities via ER-independent mechanism in cancer cells. These compounds are expected to overcome the therapeutic limitation of existing ER agonists such as estradiol and tamoxifen, which have been known to induce the proliferation of cancer cells. (C) 2016 Elsevier Ltd. All rights reserved.
A practical and efficient method for the direct trifluoromethylthiolation of unactivated C(sp3)H bonds by AgSCF3/K2S2O8 under mild conditions is described. The reaction has a good functional‐group tolerance and good selectivity. Initial mechanistic investigations indicate that the reaction may involve a radical process in which K2S2O8 plays key roles in both the activation of the C(sp3)H bond and
[EN] METHOD OF TREATING CANCER WITH A COMBINATION OF BENZYLIDENEGUANIDINE DERIVATIVES AND CHEMOTHERAPEUTIC AGENT.<br/>[FR] PROCÉDÉ DE TRAITEMENT DE CANCER AVEC UNE COMBINAISON DE DÉRIVÉS DE BENZYLIDÈNEGUANIDINE ET D'AGENT CHIMIOTHÉRAPEUTIQUE
申请人:INFLECTIS BIOSCIENCE
公开号:WO2017021216A1
公开(公告)日:2017-02-09
The present invention relates to a composition for use in treating a glioma or ameliorating the effects of a glioma, particularly glioblastoma, wherein said composition comprises a first active agent selected from the group consisting of a compound of formula (I), or a pharmaceutically acceptable salt thereof, (I) and a second active agent, which is temozolomide, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
[EN] O-ALKYL-BENZYLIDENEGUANIDINE DERIVATIVES AND THERAPEUTIC USE FOR THE TREATMENT OF DISORDERS ASSOCIATED AN ACCUMULATION OF MISFOLDED PROTEINS<br/>[FR] DÉRIVÉS D'O-ALKYL-BENZYLIDÈNEGUANIDINE ET LEUR UTILISATION THÉRAPEUTIQUE POUR LE TRAITEMENT DE TROUBLES ASSOCIÉS À UNE ACCUMULATION DE PROTÉINES MAL REPLIÉES
申请人:INFLECTIS BIOSCIENCE
公开号:WO2016001390A1
公开(公告)日:2016-01-07
The present invention relates to a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof Formula (I), and its uses to treat a disorder associated with protein misfolding stress and in particular with an accumulation of misfolded proteins.
O-alkyl-benzylideneguanidine derivatives and therapeutic use for the treatment of disorders associated an accumulation of misfolded proteins
申请人:INFLECTIS BIOSCIENCE
公开号:US10544093B2
公开(公告)日:2020-01-28
The present invention relates to a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof Formula (I), and its uses to treat a disorder associated with protein misfolding stress and in particular with an accumulation of misfolded proteins.